and one pneumococcal polysaccharide vaccine (PPSV23) for protection against pneumococcal disease. A serotype is a variation of a bacterium or virus. The immune system may react differently to ...

pneumococcal polysaccharide vaccine (PPSV23), which is recommended for all adults 65 years or older and for those over age 2 with certain risk factors. The two protect only against the form of ...

Although pneumococcal polysaccharide vaccine is a standard preventive intervention — and serves as a "quality indicator" in some settings — controversy over its effectiveness simmers in the ...

Advisory Committee on Immunization Practices (ACIP) has lowered the recommended age for pneumococcal vaccination from 65 to ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...

Pneumococcal vaccine polyvalent ... patients received either meningococcal polysaccharide serogroup A or placebo. The 6- and 12-valent vaccines achieved a protective efficacy of 76% and 92% ...

Pneumococcal 20-valent conjugate vaccine ... followed 1 month later with 23-valent polysaccharide vaccine (PPSV23). The immune responses to Prevnar 20 in patients aged 18 to 59 years were also ...

Vaccination with 23-valent pneumococcal polysaccharide vaccines has been shown to elicit only low response rates as a result of immunologic immaturity of the recipients. A study by Meisel et al.

Unlike the Conjugate pneumococcal vaccine (PCV), the PPSV vaccine is made with the Polysaccharide (sugars) of the pneumococcal bacteria. It is primarily recommended for the age group of 65 and older.